Navigation Links
BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
Date:9/13/2012

LYNBROOK, N.Y., Sept. 13, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the upcoming UBS Global Life Sciences Conference at 1:30 pm EDT on Thursday, September 20, 2012 in New York, NY.

The live webcast of this presentation may be accessed under "Calendar of Events" in the Investor Relations section of BioSpecifics' website at www.biospecifics.com or at the link http://cc.talkpoint.com/ubsx001/091912a_im/?entity=41_RNQXBE6. A replay of the webcast will also be available on the Company's website following the presentation.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Currently, injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnershi
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
5. UV Flu Technologies Expands Its International Footprint
6. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
7. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
8. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
9. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
10. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
11. Animal Biotechnology - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... yet often overlooked factor in the medical application ... of aggregation on both radiofrequency heating and magnetic ... nanoparticles (IONPs), including detailed analysis of the aggregate ... shown to produce significant reductions in both heating ... method to quantify and correlate these effects for ...
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... and Trademark Office (PTO) has issued a patent related ... weight loss. NB32 is a fixed-dose combination of naltrexone ... Patent No. 8,815,889 claims methods for treating insulin resistance ... expires in 2024. If NB32 is approved for use ...
(Date:9/2/2014)... Rocky Mount, NC (PRWEB) September 02, 2014 ... the establishment of its 11th clinical research site: PMG ... has assumed ownership and operation of the clinical research ... NC, further expanding PMG’s presence in eastern North Carolina. ... 130,000 patients. For the patients in Rocky Mount and ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... HIGHLIGHTS:2010 Results (all percentages are to comparable periods in 2009) ... a new quarterly high. Q4 sales grew by 2% and 3% ... sales increased 6% and 5% on a reported and currency adjusted ... was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 diluted ...
... new type of biological and chemical sensor that has few ... long-lasting. The "diffraction-based" sensors are made of thin stripes ... contracts depending on the acidity of its environment. Recent ... to precisely determine pH - a measure of how acidic ...
... RATON, Fla., Feb. 8, 2011 Stem Cell Assurance, ... engagement of Marcum LLP to audit its financial statements as ... then ended.  Ranked 15th among the "Top 25 Firms" by ... more than 1,100 professionals, including more than 150 partners, in ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Hydrogels used to make precise new sensor 2Hydrogels used to make precise new sensor 3Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors 2
(Date:9/2/2014)... [Brown University] It,s hard to comprehend how bad ... has become without knowing what it was before people ... rate was 10 times lower than scientists had thought, ... worse. , Extinctions are about 1,000 times more frequent ... came along. The explanation from lead author Jurriaan de ...
(Date:9/2/2014)... that professional baseball pitchers with poor core stability are more ... season because of injury than are pitchers who have good ... In the study, 347 pitchers were assessed for lumbopelvic control ... as they raised a leg to step up were up ... days cumulative, not consecutive during the season than ...
(Date:9/2/2014)... led by researchers at the University of Warwick in ... just published in the Journal Early Human Development ... spent in hospital after birth and the use of ... in preterm children. , Mathematic abilities are crucial for ... in very preterm children. Earlier studies of children who ...
Breaking Biology News(10 mins):Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2
... detection techniques developed at the University, the team mapped ... and developed a model of their likely distribution as ... action is needed. University of Canberra professor in ... found foxes are widespread in northern and eastern Tasmania ...
... University of Southampton has shown that copper can ... to the increasing number of antibiotic-resistant infections worldwide. ... largely responsible for the development of antibiotic-resistance, which ... healthcare-associated infections (HCAIs). The newly-published paper, which ...
... Institution are rolling out results from the new Airborne ... at the American Geophysical Union (AGU) meetings in San ... uncovering a previously invisible ecological world. To watch a ... the world in a whole new way, click here. ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: